SG11201803834UA - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents
Methods for treating conditions associated with masp-2 dependent complement activationInfo
- Publication number
- SG11201803834UA SG11201803834UA SG11201803834UA SG11201803834UA SG11201803834UA SG 11201803834U A SG11201803834U A SG 11201803834UA SG 11201803834U A SG11201803834U A SG 11201803834UA SG 11201803834U A SG11201803834U A SG 11201803834UA SG 11201803834U A SG11201803834U A SG 11201803834UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- masp
- rule
- methods
- pct
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 4
- 230000024203 complement activation Effects 0.000 title abstract 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 4
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 101150038444 Ment gene Proteins 0.000 abstract 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Power Steering Mechanism (AREA)
- Exhaust Gas After Treatment (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111111111111111111011111111011111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ....r „...1 WO 2017/083371 Al 18 May 2017 (18.05.2017) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) A61P A61K 39/395 (2006.01) C07K A61P 7/02 (2006.01) (21) International Application Number: (22) International Filing Date: 9 November (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/252,814 9 November 2015 (09.11.2015) 62/406,726 11 October 2016 (11.10.2016) (71) Applicants: OMEROS CORPORATION Elliott Avernue West Seattle, WA 98119 (US). UNIVER- SITY OF LEICESTER [GB/GB]; Leicestershire LE1 7RH (GB). _ (72) Inventors; and (74) Agent: QUINTON, Tineka, J.; Omeros Corporation, 201 37/02 (2006.01) Elliott Avenue West, Seattle, WA 98119 (US). 16/40 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/US2016/061113 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 2016 (09.11.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, US ZW. US (84) Designated States (unless otherwise indicated, for every [US/US]; 201 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, University Road, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Gregory, A. [US/US]; SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, WA 98040 (US). GW, KM, ML, MR, NE, SN, TD, TG). NE 36th Street Bel- Hans-Wilhelm Declarations under Rule 4.17: Leicestershire LE18 — as to the identity of the inventor (Rule 4.17(0) [Continued on next page] — (71) Applicants : DEMOPULOS, 4845 Forest Avenue SE, Seattle, DUDLER, Thomas [CH/US]; 13410 = levue, WA 98005 SCHWAEBLE, (US). 36 The Green, Mountsorrel, [DE/GB]; 3GF (GB). = = = = LDH = 100 *** CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIV- Change from Baseline over Time *p-x0.05 .* p<0 01 p4) 001 (54) Title: METHODS FOR TREATING ATION = = = = 200- W . = _ 5 provides associated an amount *. * Lestimnalple Biwa@ Waak 7 6 8 9 10 11 12 ViIcelcs 4 4 3 2 2 3 FIG. 59 methods of inhibiting the effects of MASP-2-dependent complement activation with hematopoietic stem cell transplant. The methods comprise the step of ad- of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent comple- = -144 _ -200 __ -300 Il -500 11 Ir...' M en No. ofPaticats GC 0 IN 1-1 N (57) : In one aspect, the invention in a human subject suffering from TMA C ministering, to a subject in need thereof, ment activation. WO 2017/083371 Al MIDEDIMOMMIDIROMMIEMERNMOMOVOIMIE — as to applicant's entitlement to a patent (Rule 4.17(0) Published: apply for and be granted — with sequence listing part of description (Rule 5.2(a)) — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252814P | 2015-11-09 | 2015-11-09 | |
| US201662406726P | 2016-10-11 | 2016-10-11 | |
| PCT/US2016/061113 WO2017083371A1 (en) | 2015-11-09 | 2016-11-09 | Methods for treating conditions associated with masp-2 dependent complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803834UA true SG11201803834UA (en) | 2018-06-28 |
Family
ID=58691444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011469UA SG10202011469UA (en) | 2015-11-09 | 2016-11-09 | Methods for treating conditions associated with masp-2 dependent complement activation |
| SG11201803834UA SG11201803834UA (en) | 2015-11-09 | 2016-11-09 | Methods for treating conditions associated with masp-2 dependent complement activation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011469UA SG10202011469UA (en) | 2015-11-09 | 2016-11-09 | Methods for treating conditions associated with masp-2 dependent complement activation |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20170137537A1 (en) |
| EP (1) | EP3373963A4 (en) |
| JP (2) | JP6814802B2 (en) |
| KR (2) | KR102432062B1 (en) |
| CN (2) | CN108472347B (en) |
| AU (2) | AU2016354117B2 (en) |
| BR (1) | BR112018009311A8 (en) |
| CA (1) | CA3004753C (en) |
| CL (1) | CL2018001258A1 (en) |
| EA (1) | EA201891132A1 (en) |
| GE (2) | GEP20247583B (en) |
| IL (2) | IL259225B (en) |
| MD (1) | MD4685C1 (en) |
| MX (2) | MX2018005165A (en) |
| MY (1) | MY197758A (en) |
| NZ (1) | NZ742987A (en) |
| PH (1) | PH12018501009A1 (en) |
| SG (2) | SG10202011469UA (en) |
| UA (1) | UA124094C2 (en) |
| WO (1) | WO2017083371A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5937197B2 (en) | 2011-04-08 | 2016-06-22 | ユニバーシティー オブ レスター | Methods for treating conditions associated with MASP-2-dependent complement activation |
| RU2020111211A (en) | 2013-10-17 | 2021-11-08 | Омерос Корпорейшн | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT ACTIVATION OF COMPLEMENT |
| JP2019524220A (en) * | 2016-07-06 | 2019-09-05 | マイクロオプティクス インコーポレイテッド | Glaucoma treatment apparatus and method |
| JOP20170170B1 (en) | 2016-08-31 | 2022-09-15 | Omeros Corp | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
| TWI818919B (en) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
| AU2018322032A1 (en) * | 2017-08-25 | 2020-03-12 | Omeros Corporation | Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome |
| AU2019288459A1 (en) * | 2018-06-22 | 2021-02-04 | Omeros Corporation | Compositions and methods of inhibiting MASP-2 for the treatment of various thrombotic diseases and disorders |
| CA3159172A1 (en) | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
| AU2020395306A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| US11661418B2 (en) | 2019-12-04 | 2023-05-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2024118840A1 (en) | 2022-11-30 | 2024-06-06 | Omeros Corporation | Fused pyrimidines as masp-2 inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (en) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | Tissue-friendly collagen and its manufacturing method |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| WO1989005852A1 (en) | 1987-12-15 | 1989-06-29 | Macphillamy Cummins & Gibson | Ribozymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| ATE149841T1 (en) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | VACCINES AGAINST CANCER AND INFECTIOUS DISEASES |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| RU2271825C2 (en) | 1999-07-21 | 2006-03-20 | Омерос Корпорейшн | Solutions and methods for inhibiting pain, cartilage inflammation and destruction |
| JP2003507338A (en) * | 1999-08-13 | 2003-02-25 | ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド | Lectin complement pathway (LCP) inhibitors and uses thereof |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | Compositions and methods for systemic inhibition of cartilage degradation |
| CN100519643C (en) | 2002-07-19 | 2009-07-29 | 奥默罗斯公司 | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| US20130266559A1 (en) | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| JP5937197B2 (en) * | 2011-04-08 | 2016-06-22 | ユニバーシティー オブ レスター | Methods for treating conditions associated with MASP-2-dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| DK2704743T3 (en) | 2011-05-04 | 2020-05-25 | Omeros Corp | Compositions for inhibiting masp-2 dependent complement acitivation |
| SI2861246T1 (en) * | 2012-06-18 | 2021-08-31 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| CA3124553A1 (en) | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
| EP3750914A1 (en) * | 2013-09-16 | 2020-12-16 | Children's Hospital Medical Center | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
| RU2020111211A (en) * | 2013-10-17 | 2021-11-08 | Омерос Корпорейшн | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT ACTIVATION OF COMPLEMENT |
| KR102011118B1 (en) * | 2018-04-13 | 2019-08-14 | 김정범 | Improved snap button |
-
2016
- 2016-11-09 US US15/347,434 patent/US20170137537A1/en not_active Abandoned
- 2016-11-09 JP JP2018523485A patent/JP6814802B2/en active Active
- 2016-11-09 GE GEAP201615512A patent/GEP20247583B/en unknown
- 2016-11-09 IL IL259225A patent/IL259225B/en unknown
- 2016-11-09 CA CA3004753A patent/CA3004753C/en active Active
- 2016-11-09 NZ NZ742987A patent/NZ742987A/en unknown
- 2016-11-09 UA UAA201806416A patent/UA124094C2/en unknown
- 2016-11-09 SG SG10202011469UA patent/SG10202011469UA/en unknown
- 2016-11-09 MD MDA20180042A patent/MD4685C1/en active IP Right Grant
- 2016-11-09 MY MYPI2018000685A patent/MY197758A/en unknown
- 2016-11-09 GE GEAP201614803A patent/GEP20237574B/en unknown
- 2016-11-09 IL IL295200A patent/IL295200A/en unknown
- 2016-11-09 MX MX2018005165A patent/MX2018005165A/en unknown
- 2016-11-09 CN CN201680078141.2A patent/CN108472347B/en active Active
- 2016-11-09 KR KR1020217021393A patent/KR102432062B1/en active IP Right Grant
- 2016-11-09 AU AU2016354117A patent/AU2016354117B2/en active Active
- 2016-11-09 WO PCT/US2016/061113 patent/WO2017083371A1/en active Application Filing
- 2016-11-09 EA EA201891132A patent/EA201891132A1/en unknown
- 2016-11-09 EP EP16864904.4A patent/EP3373963A4/en active Pending
- 2016-11-09 KR KR1020187016413A patent/KR102277166B1/en active IP Right Grant
- 2016-11-09 BR BR112018009311A patent/BR112018009311A8/en active Search and Examination
- 2016-11-09 CN CN202310900928.4A patent/CN117398458A/en active Pending
- 2016-11-09 SG SG11201803834UA patent/SG11201803834UA/en unknown
-
2018
- 2018-04-25 MX MX2023001193A patent/MX2023001193A/en unknown
- 2018-05-08 PH PH12018501009A patent/PH12018501009A1/en unknown
- 2018-05-09 CL CL2018001258A patent/CL2018001258A1/en unknown
-
2020
- 2020-02-28 AU AU2020201500A patent/AU2020201500A1/en not_active Abandoned
- 2020-08-04 US US16/984,509 patent/US11981749B2/en active Active
- 2020-12-21 JP JP2020210933A patent/JP2021063093A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |